Bharat Immunological Biological Corporation Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.3 as of 06 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Supriya Lifescience Ltd for the Dec '25 is ₹ 209.05 crore as compare to the Sep '25 revenue of ₹ 202.56 crore. This represent the growth of 3.2% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Supriya Lifescience Ltd for the Dec '25 is ₹ 74.24 crore as compare to the Sep '25 ebitda of ₹ 75.37 crore. This represent the decline of -1.5% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 49.68 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Supriya Lifescience Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Supriya Lifescience Ltd is 5,661 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Supriya Lifescience Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Supriya Lifescience Ltd?

As of May 6, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.3. On the other hand, Supriya Lifescience Ltd stock price is INR ₹703.45.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.